Use of Shear Wave Elastography to Assess Non-alcoholic Fatty Liver Disease (NAFLD)
NCT ID: NCT03587298
Last Updated: 2021-03-10
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
80 participants
OBSERVATIONAL
2018-09-15
2021-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Assessment of Hepatic Fibrosis by Shear Wave Elastography in Patients With Liver Malignancy: A Prospective Single-center Study
NCT02958592
Liver Fibrosis Assessment With ShearWave Elastography
NCT02181452
ShearWave™ Elastography to Assess Liver Fibrosis in Chinese Patients With Hepatitis B
NCT02313649
Liver and Spleen Stiffness Measured by 2D-SWE for Diagnosis of Liver Fibrosis in Patients With cACLD
NCT06147934
SWE Liver Stiffness as a Predictor of Progression of Chronic Liver Diseases
NCT03389152
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
It is known that the degree of fibrosis is the most important parameter for the clinical course and prognosis. In addition, patients with mild lobular inflammation or fibrosis (regardless of severity) have an increased risk of developing NASH compared to patients with exclusive steatosis. A significant number of patients with NAFL may develop fibrotising NASH (5-20%). This is particularly the case when metabolic factors continue to deteriorate.
Liver biopsy remains the gold standard for the diagnosis of NAFLD. In particular, differentiation between NAFL and NASH and the degree of fibrosis are still only possible using histology. The invasive nature of the procedure involves risks to the patient's health such as bleeding, injuries to other organs or nerves, and complications of anesthesia. Furthermore, since the biopsy is taken selectively as a liver biopsy, it is possible to test a sample that does not adequately represent the degree of actual fibrosis, since regional differences in the severity of liver fibrosis can often be present. In addition, the liver biopsy is associated with considerable costs. Accordingly, liver biopsy is not an optimal diagnostic procedure and is hardly suitable as a diagnostic method for short-term follow-up under therapy. For this reason, a reliable, non-invasive method has long been sought to diagnose NAFLD, to distinguish NASH from steatosis, to assess the degree of fibrosis and which allows a less stressful assessment of the course of the liver.
Imaging procedures are available here. B-image sonography is already routinely used in children and adolescents with suspected or proven NASH for the detection of liver remodeling processes, in particular fibrosis. B-scan sonography is an excellent method for determining the presence and extent of hepatic steatosis, but the detection and graduation of liver fibrosis using B-mode sonography is only possible in very advanced stages.
In recent years, the determination of tissue stiffness in various organ systems and their pathologies, such as the breast, tendons and liver, has been successfully used in adults. Individual reports in adults give first indications that liver remodelling processes, in particular fibrosis by means of shear wave elastography (SWE), can be diagnosed in early stages. However, the evidence of the use of SWE in children to assess liver parenchyma changes, especially in NAFLD, is still insufficient. Therefore, in this study it will be investigated whether the rt-SWE provides reproducible values for liver stiffness and fibrosis in children and adolescents and by that a reliably diagnosis of NAFLD and assessment of the degree of fibrosis is possible.
The planned clinical examination and blood collection for laboratory chemical examinations are part of the routine follow-up of patients with obesity and steatosis hepatis. There will be no additional examinations, so there will be no greater burden on the young patients and no additional time expenditure.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Group 1
NAFLK criteria met (by definition: sonographic fatty liver)
Real-Time (Supersonic)- 2D shear wave elastography (rt-SWE)
The SWE is carried out intercostally. If possible, the patient should hold the breath for 5-10 seconds. So-called colour charts are used, which indicate the derived liver stiffness in colour-coded form. In addition to the visual assessment of these colour charts, the quantitative ROI-based measurement of the SWE in kPa is performed in the "hardest" appearing areas. The measurement is performed at 5 different sites of the liver parenchyma and all SWE values are recorded.
Group 2
Control group: matched age; no NAFKL
Real-Time (Supersonic)- 2D shear wave elastography (rt-SWE)
The SWE is carried out intercostally. If possible, the patient should hold the breath for 5-10 seconds. So-called colour charts are used, which indicate the derived liver stiffness in colour-coded form. In addition to the visual assessment of these colour charts, the quantitative ROI-based measurement of the SWE in kPa is performed in the "hardest" appearing areas. The measurement is performed at 5 different sites of the liver parenchyma and all SWE values are recorded.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Real-Time (Supersonic)- 2D shear wave elastography (rt-SWE)
The SWE is carried out intercostally. If possible, the patient should hold the breath for 5-10 seconds. So-called colour charts are used, which indicate the derived liver stiffness in colour-coded form. In addition to the visual assessment of these colour charts, the quantitative ROI-based measurement of the SWE in kPa is performed in the "hardest" appearing areas. The measurement is performed at 5 different sites of the liver parenchyma and all SWE values are recorded.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* obesity with a BMI above percentile 95 according to Kromeyer-Hauschild
* NAFLD criteria met (by definition: sonographic fatty liver)
* written informed consent
* patients of matching age are included in the control group without any indication of NAFLD
Exclusion Criteria
* alcohol consumption (more than 20g for girls and 30g for boys per day), after explicit anamnesis
* persons who are accommodated in an institution by court or official order
6 Years
18 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
RWTH Aachen University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Angeliki Pappas, Dr. med.
Role: PRINCIPAL_INVESTIGATOR
Paediatric Clinic; RWTH Aachen University Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Paediatric Clini; RWTH Aachen University Hospital
Aachen, North Rhine-Westphalia, Germany
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
18-056
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.